



## Epigenetic Modulation for Cancer Therapy

Guest Editor:

**Dr. Zheng-Yuan Su**

Department of Bioscience  
Technology, Chung Yuan  
Christian University, Taoyuan  
City 320314, Taiwan

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editor

Dear Colleagues,

Epigenetic modulation for cancer therapy is an emerging and promising approach in the field of oncology. Heritable changes in gene expression that occur without any changes to the DNA sequence are called epigenetics. In cancer, genes that promote tumor growth, invasion, and metastasis may be expressed aberrantly due to epigenetic modifications. Cancer therapy has become more attractive by targeting epigenetic changes. The aim of this Special Issue is to provide a platform on which to share cutting-edge discoveries, novel strategies, and therapeutic approaches that target epigenetic modifications in cancer. Submissions can cover a range of topics, including, but not limited to, the following:

- DNA methylation inhibitors used for the treatment of cancer.
- Histone-modification-targeted therapies to treat various cancer types.
- Non-coding RNAs as epigenetic regulators in cancer.
- Epigenetic biomarkers in the diagnosis and prognosis of cancer.
- Epigenetic-based combination therapies.
- Mechanisms involved in epigenetic dysregulation in diverse cancer subtypes.
- Potential of epigenetic editing for precision cancer medicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)